M&A Deal Summary

Meridian Bioscience Acquires GenePOC - State-of-the-Art Molecular Diagnostics Platform

On April 30, 2019, Meridian Bioscience acquired life science company GenePOC - State-of-the-Art Molecular Diagnostics Platform from GenePOC for 120M USD

Acquisition Highlights
  • This is Meridian Bioscience’s 3rd transaction in the Life Science sector.
  • This is Meridian Bioscience’s largest (disclosed) transaction.
  • This is Meridian Bioscience’s 1st transaction in Canada.
  • This is Meridian Bioscience’s 1st transaction in Quebec.

M&A Deal Summary
Date 2019-04-30
Target GenePOC - State-of-the-Art Molecular Diagnostics Platform
Sector Life Science
Buyer(s) Meridian Bioscience
Sellers(s) GenePOC
Deal Type Divestiture
Deal Value 120M USD

Target

GenePOC - State-of-the-Art Molecular Diagnostics Platform

Québec, Quebec, Canada
GenePOC, Inc. - State-of-the-Art Molecular Diagnostics Platform provides a sample to result testing for single tests, as well as flexible multiplexing capability.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Meridian Bioscience

Cincinnati, Ohio, United States
Category Company
Founded 1976
Sector Life Science
Employees702
Revenue 318M USD (2021)
DESCRIPTION

Meridian is a life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Meridian was founded in 1976 and is based in Cincinnati, Ohio.

DEAL STATS #
Overall 8 of 11
Sector (Life Science) 3 of 5
Type (Divestiture) 3 of 4
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-24 Magellan Biosciences

Chelmsford, Massachusetts, United States

Magellan Biosciences, Inc. is a developer and manufacturer of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-02-19 Exalenz Bioscience

Modiin, Israel

Exalenz Bioscience, Inc. develops and markets diagnostic tests and monitoring systems that use the breath to diagnose and help manage gastrointestinal and liver conditions. Exalenz ’s flagship BreathID® Hp Systems offer the most efficient and accurate test for detection of H. pylori bacteria, associated with various illnesses including gastric cancer, and is already in use in over 400 U.S. medical centers and major labs across the country. Exalenz holds regulatory approvals in the United States, Europe, China, and Israel for H. pylori detection and is currently evaluating additional applications of the BreathID platform.

Buy $49M

Seller(S) 1

SELLER

GenePOC

Québec, Quebec, Canada
Category Company
Founded 2007
Sector Medical Products
DESCRIPTION

GenePOC, Inc. is a developer of accurate and cost-effective molecular solutions to detect pathogen genes. GenePOC, Inc. was founded in 2007 and is based in Québec, Canada.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal